Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zymeworks

Explore full profile

Computational biotechnology company that is focused on optimizing therapeutic antibodies and other protein-based therapeutics

Vancouver, CanadaFounded 2003Biotech & Life Sciences
Valuation $1.27B Market cap · 2026
Revenue $293M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Zymeworks

Zymeworks is a biopharmaceutical company focused on developing multifunctional therapeutics for patients with difficult-to-treat cancers and other serious diseases. Operating in the biotechnology sector, Zymeworks serves healthcare providers, research institutions, and pharmaceutical companies. The company leverages its proprietary technology platforms to create antibody-drug conjugates and multispecific antibody therapeutics. Zymeworks generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the commercialization of its own therapeutic products. The company's integrated R&D engine, from target selection to pivotal studies, is driven by a team of world-class researchers dedicated to discovering, developing, and commercializing novel agents globally.

Source: Dealroom company data

At a glance

Founded
2003
Headquarters
Vancouver, Canada
Listing
IPO 2017
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Research & analysis

From the Dealroom knowledge graph
News Zymeworks lands $250M milestone as Ziihera wins first-line cancer approval Aug 27, 2026 News Zymeworks to buy Theravance Biopharma for $929M, adding COPD drug Jun 29, 2026

Latest news

Press, funding announcements and product moves mentioning Zymeworks.

See all news

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • WUTIF
  • CTI Capital
  • Celgene
  • Eli Lilly

Series B and later14 investors entered at this stage

  • CTI Life Sciences
  • Fonds de solidarité FTQ
  • Lumira Ventures
  • Business Development Bank of Canada
  • Teralys Capital
  • Brace Pharma
  • BDC Capital
  • Merlin Nexus
  • Northleaf
  • Raymond James
  • MTS Health Partners
  • Wells Fargo Securities Canada
  • Citi
  • Royalty Pharma

Talent

Book a demo to see the people
Team profiled 31 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇨🇦 Canada67.3%
🇺🇸 United States27.6%
🇸🇬 Singapore1.6%
🇮🇪 Ireland1.2%
🇬🇧 United Kingdom1.2%
Top 5 of 8 shown
Web traffic by country
22K monthly visits
across markets
🇨🇦 Canada59.1%
🇺🇸 United States28.2%
🇮🇳 India4.5%
🇯🇵 Japan4.1%
🇫🇷 France1.8%
Top 5 markets shown

Patents

Estimated portfolio value
$125M

84 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zymeworks on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zymeworks on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles